Tildrakizumab-Asmn (Ilumya)

Ilumya (tildrakizumab‑asmn) is covered only for adults (≥18) with FDA‑approved moderate‑to‑severe plaque psoriasis who are candidates for systemic therapy or phototherapy and is limited to FDA‑approved indications. Initial approval (3 months) requires dermatologist prescribing/consultation and documentation of either a 3‑month trial/intolerance to at least one biologic or a 3‑month trial/intolerance to at least one traditional systemic agent (or methotrexate contraindication); renewals (12 months) require documented response, with recommended dosing 100 mg SC at weeks 0 and 4, then every 12 weeks.

"Ilumya is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy."

Sign up to see full coverage criteria, indications, and limitations.